Molecular markers to predict response to therapy

Seminars in Oncology

Volumn 40, Issue 4, 2013, Pages 444-458

  Garcia Donas, Jesus ^a,b   Rodriguez Antona, Cristina ^b   Jonasch, Eric ^c  

^a Gynecolog ical and Genitourinary Tumors Programme Centro Integra Oncologico Clara Campal CIOCC   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; AXITINIB; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CYCLOPHOSPHAMIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FORETINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MOLECULAR MARKER; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; S6 KINASE; SCATTER FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; AREA UNDER THE CURVE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CIRCULATING TUMOR CELL; COPY NUMBER VARIATION; DNA POLYMORPHISM; DRUG METABOLISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE INACTIVATION; HAPLOINSUFFICIENCY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY METASTASIS; MICROENVIRONMENT; OVARY CANCER; PATIENT AUTONOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; REVIEW; RIBOSOME SUBUNIT; SOMATIC MUTATION; SUPPRESSOR CELL; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84883175872     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.05.005     Document Type: Article

References (91)

1. D.C. Danila, M. Fleisher, and H.I. Scher Circulating tumor cells as biomarkers in prostate cancer Clin Cancer Res 17 12 2011 3903 3912
2. S. Signoretti, G. Bratslavsky, and F.M. Waldman Tissue-based research in kidney cancer: current challenges and future directions Clin Cancer Res 14 12 2008 3699 3705
3. A.F. Baker, T. Dragovich, N.T. Ihle, R. Williams, C. Fenoglio-Preiser, and G. Powis Stability of phosphoprotein as a biological marker of tumor signaling Clin Cancer Res 11 12 2005 4338 4340
4. M. Srinivasan, D. Sedmak, and S. Jewell Effect of fixatives and tissue processing on the content and integrity of nucleic acids Am J Pathol 161 6 2002 1961 1971
5. B. Ljungberg, R. Stenling, and G. Roos DNA content in renal cell carcinoma with reference to tumor heterogeneity Cancer 56 3 1985 503 508
6. E. Oosterwijk, N.H. Bander, and C.R. Divgi Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250 J Clin Oncol 11 4 1993 738 750
7. M. Gerlinger, A.J. Rowan, and S. Horswell Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 2012 883 892
8. M.H. Bui, D. Seligson, and K.R. Han Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clin Cancer Res 9 2 2003 802 811
9. M. Atkins, M. Regan, and D. McDermott Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer Clin Cancer Res 11 10 2005 3714 3721
10. M.P. Upton, R.A. Parker, A. Youmans, D.F. McDermott, and M.B. Atkins Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy J Immunother 28 5 2005 488 495
11. D.F. McDermott, M.S. Ghebremichael, and S. Signoretti The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC) J Clin Oncol 28 15s 2010:abstr 4514
12. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
13. J.R. Gnarra, K. Tory, and Y. Weng Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 1 1994 85 90
14. B.I. Rini, E. Jaeger, and V. Weinberg Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status Br J Urol. Intern 98 4 2006 756 762
15. T.K. Choueiri, S.A. Vaziri, and E. Jaeger von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma J Urol 180 3 2008 860 865
16. C. Pena, C. Lathia, M. Shan, B. Escudier, and R.M. Bukowski Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Clin Cancer Res 16 19 2010 4853 4863
17. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma The New England journal of medicine 356 2 2007 Jan 11 125 134
18. T.K. Choueiri, M.M. Regan, and J.E. Rosenberg Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy BJU Int 106 6 2010 772 778
19. T.K. Choueiri, S. Cheng, A.Q. Qu, J. Pastorek, M.B. Atkins, and S. Signoretti Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET) Urol Oncol 2012 Nov 7 [article in press]
20. E. Jonasch, P. Corn, and L.C. Pagliaro Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis Cancer 116 1 2010 57 65
21. E. Jonasch, C.G. Wood, and S.F. Matin Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 27 25 2009 4076 4081
22. D. Tsavachidou-Fenner, N. Tannir, and P. Tamboli Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma Ann Oncol 21 8 2010 1599 1606
23. D. Cho, S. Signoretti, and S. Dabora Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma Clin Genitourinary Cancer 5 6 2007 379 385
24. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 2007 2271 2281
25. R.A. Figlin, P. de Souza, and D. McDermott Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha Cancer 115 16 2009 3651 3660
26. T.K. Choueiri, U. Vaishampayan, and J.E. Rosenberg Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma J Clin Oncol 31 2 2013 181 186
27. F.A. Monzon, K. Alvarez, and L. Peterson Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis Mod Pathol 2011 Jul 1
28. T. Klatte, P.N. Rao, and M. de Martino Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma J Clin Oncol 27 5 2009 746 753
29. T. Yoshimoto, K. Matsuura, and S. Karnan High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma J Pathol 213 4 2007 392 401
30. T. Klatte, N. Kroeger, and E.N. Rampersaud Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma Cancer 118 23 2012 5777 5782
31. F. Latif, K. Tory, and J. Gnarra Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 5112 1993 1317 1320
32. G.L. Dalgliesh, K. Furge, and C. Greenman Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes Nature 463 7279 2010 360 363
33. I. Varela, P. Tarpey, and K. Raine Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma Nature 469 7331 2011 539 542
34. S. Pena-Llopis, S. Vega-Rubin-de-Celis, and A. Liao BAP1 loss defines a new class of renal cell carcinoma Nat Genet 44 7 2012 751 759
35. C. Shen, R. Beroukhim, and S.E. Schumacher Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene Cancer Discov 1 3 2011 222 235
36. G. Hudes, J. Pei, and Y. Liu Correlation of chromosome (Chr) 14 loss and 5q gain with outcomes of pazopanib treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) J Clin Oncol 2012 30 suppl: abstract 4605
37. W.E. Evans, and M.V. Relling Moving towards individualized medicine with pharmacogenomics Nature 429 6990 2004 464 468
38. M. Ingelman-Sundberg Pharmacogenomic biomarkers for prediction of severe adverse drug reactions N Engl J Med 358 6 2008 637 639
39. B.P. Schneider, M. Wang, and M. Radovich Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 28 2008 4672 4678
40. M.C. Etienne-Grimaldi, J. Bennouna, and J.L. Formento Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan Br J Clin Pharmacol 73 5 2012 776 785
41. F. Loupakis, A. Ruzzo, and L. Salvatore Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer BMC Cancer 11 2011 247
42. A.K. Koutras, A.G. Antonacopoulou, and A.G. Eleftheraki Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab Pharmacogenomics J 12 6 2012 468 475
43. A.M. Schultheis, G. Lurje, and K.E. Rhodes Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab Clin Cancer Res 14 22 2008 7554 7563
44. C.J. Peer, T.M. Sissung, and A. Kim Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia Clin Cancer Res 18 7 2012 2099 2107
45. L. Jain, T.M. Sissung, and R. Danesi Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib J Exp Clin Cancer Res 29 2010 95
46. N.P. van Erp, K. Eechoute, and A.A. van der Veldt Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity J Clin Oncol 27 26 2009 4406 4412
47. N.P. van Erp, R.H. Mathijssen, and A.A. van der Veldt Myelosuppression by sunitinib is flt-3 genotype dependent Br J Cancer 103 5 2010 757 758
48. T. Mizuno, T. Terada, and T. Kamba ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma Ann Oncol 21 6 2010 1382 1383
49. J. Garcia-Donas, E. Esteban, and L.J. Leandro-Garcia Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study Lancet Oncol 12 12 2011 1143 1150
50. J.J. Kim, S.A. Vaziri, and B.I. Rini Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib Cancer 118 7 2012 1946 1954
51. A.A. van der Veldt, K. Eechoute, and H. Gelderblom Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib Clin Cancer Res 17 3 2011 620 629
52. Beuselinck BKA, Couchy G, et al. A pharmacogenomic scoring system predicting median time to progression (mTTP) on sunitinib (SUN) as first-line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2012;30 suppl 5: abstract 359.
53. C.F. Xu, N.X. Bing, and H.A. Ball Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes J Clin Oncol 29 18 2011 2557 2564
54. B. Escudier, A.K. Loomis, and A. Kaprin Association of single nucleotide polymorphisms (SNPS) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of Axitinib Versus Sorafenib (AXIS Trial) cell carcinoma (mRCC) in the phase 3 trial of Axitinib Versus Sorafenib (AXIS Trial) Eur J Cancer 47 S505 2012
55. M. Brennan, J.A. Williams, Y. Chen, M. Tortorici, Y. Pithavala, and Y.C. Liu Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics Eur J Clin Pharmacol 68 5 2012 645 655
56. D. Kniepeiss, W. Renner, and O. Trummer The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation Clin Transplant 25 1 2011 146 150
57. N. Picard, K. Rouguieg-Malki, N. Kamar, L. Rostaing, and P. Marquet CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients Transplantation 91 6 2011 652 656
58. C. Rodriguez-Antona, and J. Garcia-Donas Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma Pharmacogenomics 13 14 2012 1621 1633
59. A.A. van der Veldt, K. Eechoute, and H. Gelderblom Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib Clin Cancer Res 17 3 2010 620 629
60. Beuselinck B, Karadimou A, Couchy G, et al. A pharmacogenomic scoring system predicting median time to progression (mTTP) on sunitinib (SUN) as first-line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2012;30 suppl 5:abstract 359.
61. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 20 2009 3312 3318
62. A.J. Zurita, E. Jonasch, and X. Wang A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma Ann Oncol 23 1 2012 46 52
63. H.T. Tran, Y. Liu, and A.J. Zurita Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials Lancet Oncol 13 8 2012 827 837
64. A. Woywodt, M. Schroeder, and W. Gwinner Elevated numbers of circulating endothelial cells in renal transplant recipients Transplantation 76 1 2003 1 4
65. A. Woywodt, J. Scheer, and L. Hambach Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation Blood 103 9 2004 3603 3605
66. M. Mutin, I. Canavy, A. Blann, M. Bory, J. Sampol, and F. Dignat-George Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells Blood 93 9 1999 2951 2958
67. Y. Sakamori, K. Masago, and K. Ohmori Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer Cancer Sci 103 6 2012 1065 1070
68. S. Jain, M.M. Ward, and J. O'Loughlin Incremental increase in VEGFR1(+) hematopoietic progenitor cells and VEGFR2(+) endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients Breast Cancer Res Treat 132 1 2012 235 242
69. S.J. Shin, J.W. Hwang, J.B. Ahn, S.Y. Rha, J.K. Roh, and H.C. Chung Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent Invest New Drugs 31 1 2012 1 13
70. M. Manzoni, S. Mariucci, and S. Delfanti Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in bevacizumab-based treatment for advanced colorectal cancer J Cancer Res Clin Oncol 138 7 2012 1187 1196
71. J. Mateo, J.V. Heymach, and A.J. Zurita Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook Mol Diagn Ther 16 3 2012 151 161
72. L. Vroling, A.A. van der Veldt, and R.R. de Haas Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib Angiogenesis 12 1 2009 69 79
73. V. Gruenwald, G. Beutel, S. Schuch-Jantsch, C. Reuter, P. Ivanyi, A. Ganser, and M. Haubitz Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib BMC Cancer 10 2010 695
74. F. Farace, M. Gross-Goupil, and E. Tournay Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors Br J Cancer 104 7 2011 1144 1150
75. D.E. Castellano, E. Esteban, and L. Leon Mateos Prospective assessment of circulating endothelial cells (CECs) as early markers of clear cell renal cell carcinoma (CCRCC) progression in first line setting: The Circles study (SOGUG 2011-01) J Clin Oncol 30 2012 suppl
76. A. Lucci, C.S. Hall, and A.K. Lodhi Circulating tumour cells in non-metastatic breast cancer: a prospective study Lancet Oncol 13 7 2012 688 695
77. D.C. Danila, M. Fleisher, and H.I. Scher Circulating tumor cells as biomarkers in prostate cancer Clin Cancer Res 17 12 2011 3903 3912
78. J. Sastre, M.L. Maestro, and A. Gomez-Espana Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study Oncologist 17 7 2012 947 955
79. S. Riethdorf, H. Fritsche, and V. Muller Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system Clin Cancer Res 13 3 2007 920 928
80. S.A. Joosse, and K. Pantel Biologic challenges in the detection of circulating tumor cells Cancer Res 73 1 2013 8 11
81. Y. Zhang, J. Li, L. Cao, W. Xu, and Z. Yin Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives Semin Oncol 39 4 2012 449 460
82. S. Nagrath, L.V. Sequist, and S. Maheswaran Isolation of rare circulating tumour cells in cancer patients by microchip technology Nature 450 7173 2007 1235 1239
83. C.V. Pecot, F.Z. Bischoff, and J.A. Mayer A novel platform for detection of CK+ and CK- CTCs Cancer Discov 1 7 2011 580 586
84. I. Daurkin, E. Eruslanov, and T. Stoffs Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway Cancer Res 71 20 2011 6400 6409
85. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends Immunol 23 11 2002 549 555
86. D. Lindau, P. Gielen, M. Kroesen, P. Wesseling, and G.J. Adema The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells Immunology 138 2 2013 105 115
87. J.F. Jacobs, S. Nierkens, C.G. Figdor, I.J. de Vries, and G.J. Adema Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 13 1 2012 e32 e42
88. C. Medrek, F. Ponten, K. Jirstrom, and K. Leandersson The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients BMC Cancer 12 2012 306
89. F. Shojaei, X. Wu, and A.K. Malik Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells Nat Biotechnol 25 8 2007 911 920
90. J.S. Ko, P. Rayman, and J. Ireland Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained Cancer Res 70 9 2010 3526 3536
91. J. Finke, J. Ko, B. Rini, P. Rayman, J. Ireland, and P. Cohen MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy Int Immunopharmacol 11 7 2011 856 861